Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HYPD Hyperion DeFi	$7.23 -7.7%	$8.81	$0.85 ▼ $75.18	$43.87M	2.42	857,540 shs	476,745 shs
LIAN LianBio	$0.05	$0.26	$0.27 ▼ $4.99	$5.43M	0.23	1.04 million shs	203 shs
PHXM PHAXIAM Therapeutics	$3.10	$3.10	$2.50 ▼ $13.00	$10.58M	2.35	2,472 shs	N/A
RXDX Prometheus Biosciences	$199.92	$198.62	$23.27 ▼ $199.98	$9.56B	-0.49	913,102 shs	N/A

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HYPD Hyperion DeFi	-7.66%	+33.89%	-45.35%	+512.71%	-89.71%
LIAN LianBio	0.00%	-5.28%	-88.23%	-74.27%	-84.51%
PHXM PHAXIAM Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
RXDX Prometheus Biosciences	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
HYPD Hyperion DeFi	0.2882 of 5 stars	1.0	0.0	0.0	0.0	2.3	0.8	0.6
LIAN LianBio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PHXM PHAXIAM Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RXDX Prometheus Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HYPD Hyperion DeFi	2.00	Hold	$2.00	-72.34% Downside
LIAN LianBio	0.00	N/A	N/A	N/A
PHXM PHAXIAM Therapeutics	0.00	N/A	N/A	N/A
RXDX Prometheus Biosciences	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HYPD Hyperion DeFi	$60K	674.80	N/A	N/A	($695.52) per share	-0.01
LIAN LianBio	N/A	N/A	N/A	N/A	$2.71 per share	N/A
PHXM PHAXIAM Therapeutics	N/A	N/A	N/A	N/A	$7.98 per share	N/A
RXDX Prometheus Biosciences	$6.81M	1,403.55	N/A	N/A	$16.12 per share	12.40

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HYPD Hyperion DeFi	-$49.82M	-$58.40	N/A	N/A	N/A	-62,238.41%	N/A	-316.90%	N/A
LIAN LianBio	-$110.29M	-$0.81	N/A	N/A	N/A	N/A	-33.17%	-30.19%	N/A
PHXM PHAXIAM Therapeutics	-$240K	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
RXDX Prometheus Biosciences	-$141.75M	-$3.52	N/A	N/A	N/A	-3,768.76%	-33.50%	-29.59%	N/A

Latest RXDX, HYPD, PHXM, and LIAN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/19/2025	Q1 2025	HYPD Hyperion DeFi	-$7.20	-$1.59	+$5.61	-$1.59	$1.60 million	$1.60 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
HYPD Hyperion DeFi	N/A	N/A	N/A	N/A	N/A
LIAN LianBio	N/A	N/A	N/A	N/A	N/A
PHXM PHAXIAM Therapeutics	N/A	N/A	N/A	N/A	N/A
RXDX Prometheus Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HYPD Hyperion DeFi	N/A	0.34	0.34
LIAN LianBio	N/A	10.06	10.06
PHXM PHAXIAM Therapeutics	0.23	1.78	N/A
RXDX Prometheus Biosciences	0.04	37.56	37.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HYPD Hyperion DeFi	25.84%
LIAN LianBio	74.85%
PHXM PHAXIAM Therapeutics	0.40%
RXDX Prometheus Biosciences	92.66%

Insider Ownership

Company	Insider Ownership
HYPD Hyperion DeFi	10.86%
LIAN LianBio	7.59%
PHXM PHAXIAM Therapeutics	1.94%
RXDX Prometheus Biosciences	3.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HYPD Hyperion DeFi	40	5.60 million	5.00 million	Optionable
LIAN LianBio	110	108.06 million	99.86 million	Not Optionable
PHXM PHAXIAM Therapeutics	49	3.41 million	3.35 million	No Data
RXDX Prometheus Biosciences	97	47.81 million	46.19 million	Not Optionable

RXDX, HYPD, PHXM, and LIAN Headlines

Recent News About These Companies

EQS-News: Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax

November 14, 2024 | markets.businessinsider.com

Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax

November 14, 2024 | markets.businessinsider.com

Alien movies in order: The complete Alien timeline, from Prometheus to Alien: Resurrection

August 16, 2024 | digitalspy.comD

Investors fund Prometheus team's 'unfinished business' with $400M for new inflammatory biotech Mirador

March 22, 2024 | fiercebiotech.comF

Former Execs at Prometheus Biosciences Launch New Precision Medicine Firm Mirador Therapeutics

March 21, 2024 | precisionmedicineonline.comP

Mirador debuts with $400M, picking up where immune drugmaker Prometheus left off

March 21, 2024 | biopharmadive.comB

Cormorant Private Healthcare Fund III LP's Net Worth

March 6, 2024 | benzinga.com

Prometheus Biosciences Inc. [RXDX] stock for 1,084,200 USD was sold by Marshall Keith W

June 15, 2023 | knoxdaily.comK

Investing in Prometheus Biosciences Inc. (RXDX) Is Getting More Attractive

June 12, 2023 | knoxdaily.comK

Prometheus Biosciences: 8.5% IRR And Closing In A Month

May 30, 2023 | seekingalpha.com

Prometheus Biosciences (NASDAQ: RXDX)

May 28, 2023 | fool.com

Prometheus Biosciences gains after HSR waiting for sale to Merck expires

May 23, 2023 | msn.com

SHAREHOLDER ALERT: Weiss Law Investigates Prometheus Biosciences, Inc.

May 23, 2023 | barrons.com

What Makes Prometheus Biosciences (RXDX) an Attractive Investment Choice?

May 18, 2023 | finance.yahoo.com

Prometheus Biosciences, Inc. (RXDX) is a Great Momentum Stock: Should You Buy?

May 12, 2023 | finance.yahoo.com

Jefferies Downgrades Prometheus Biosciences (RXDX)

May 11, 2023 | msn.com

RBC Capital Maintains Prometheus Biosciences (RXDX) Sector Perform Recommendation

May 11, 2023 | msn.com

Prometheus Biosciences Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Progress

May 9, 2023 | yahoo.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RXDX, CVT, RADI, INFI

May 4, 2023 | kentuckytoday.comK

Abbvie, Bristol Myers competed with Merck in sale of Prometheus - report

May 1, 2023 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RXDX, HYPD, PHXM, and LIAN Company Descriptions

Hyperion DeFi NASDAQ:HYPD

$7.23 -0.60 (-7.66%)

As of 08/12/2025 04:00 PM Eastern

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.

LianBio NASDAQ:LIAN

$0.05 0.00 (0.00%)

As of 08/11/2025

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.

PHAXIAM Therapeutics NASDAQ:PHXM

$3.10 0.00 (0.00%)

As of 08/8/2025

PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.

Prometheus Biosciences NASDAQ:RXDX

Prometheus Biosciences, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of novel therapeutics for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR300, a G-protein coupled receptor modulator for IBD and potentially other immune-mediated diseases; PRA052, an anti-CD30L mAb for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated diseases; and PR2100, an anti-inflammatory cytokine mAb for IBD, and inflammatory and fibrotic diseases. It has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH for PRA052; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. The company was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. Prometheus Biosciences, Inc. was incorporated in 2016 and is headquartered in San Diego, California. As of June 16, 2023, Prometheus Biosciences, Inc. operates as a subsidiary of Merck & Co., Inc.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time